← Oncology Approval Tracker

FDA DECISION ·

Lorbrena

lorlatinib · Pfizer

Traditional approvalTraditional conversionNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with metastatic non-small cell lung cancer with an ALK-positive result on an FDA-approved test. This traditional approval broadened the earlier authorization restricted by prior ALK-inhibitor exposure.

LAMPGEN ANALYSIS

Why it matters

The action converts the original accelerated approval and enables use earlier in metastatic ALK-positive disease.

What research teams should watch

Track ALK assay results and prior therapy at the date of treatment so historical cohorts match the applicable label.

PRIMARY RECORDS

Sources